JPH07503723A - ピペラジン及びピペリジン誘導体，並びに抗精神薬としてのこれらの使用 - Google Patents

ピペラジン及びピペリジン誘導体，並びに抗精神薬としてのこれらの使用

Info

Publication number
JPH07503723A
JPH07503723A JP5513907A JP51390793A JPH07503723A JP H07503723 A JPH07503723 A JP H07503723A JP 5513907 A JP5513907 A JP 5513907A JP 51390793 A JP51390793 A JP 51390793A JP H07503723 A JPH07503723 A JP H07503723A
Authority
JP
Japan
Prior art keywords
formula
compound
butyl
piperazinyl
benzisothiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5513907A
Other languages
English (en)
Japanese (ja)
Inventor
ノーマン、マーク・ヘンリー
ナバス・ザ・サード、フランク
Original Assignee
ザ・ウエルカム・ファウンデーション・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ウエルカム・ファウンデーション・リミテッド filed Critical ザ・ウエルカム・ファウンデーション・リミテッド
Publication of JPH07503723A publication Critical patent/JPH07503723A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP5513907A 1992-02-12 1993-02-11 ピペラジン及びピペリジン誘導体，並びに抗精神薬としてのこれらの使用 Pending JPH07503723A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9202915.6 1992-02-12
GB929202915A GB9202915D0 (en) 1992-02-12 1992-02-12 Chemical compounds
PCT/GB1993/000285 WO1993016073A1 (en) 1992-02-12 1993-02-11 Piperazine and piperidine derivatives, and their use as antipsychotics

Publications (1)

Publication Number Publication Date
JPH07503723A true JPH07503723A (ja) 1995-04-20

Family

ID=10710223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5513907A Pending JPH07503723A (ja) 1992-02-12 1993-02-11 ピペラジン及びピペリジン誘導体，並びに抗精神薬としてのこれらの使用

Country Status (16)

Country Link
EP (1) EP0625978A1 (no)
JP (1) JPH07503723A (no)
KR (1) KR950700290A (no)
AU (1) AU3460393A (no)
CA (1) CA2117434A1 (no)
CZ (1) CZ194994A3 (no)
FI (1) FI943718A0 (no)
GB (1) GB9202915D0 (no)
HU (1) HUT72309A (no)
IL (1) IL104690A0 (no)
MX (1) MX9300786A (no)
NO (1) NO942977L (no)
RU (1) RU94038064A (no)
SK (1) SK96494A3 (no)
WO (1) WO1993016073A1 (no)
ZA (1) ZA93958B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514837A (ja) * 2007-01-03 2010-05-06 コーテックス ファーマシューティカルズ， インコーポレイテッド グルタミン酸作動性シナプス反応を強化するための３−置換−［１，２，３］ベンゾトリアジノン化合物

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
RU2118322C1 (ru) * 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
ATE246682T1 (de) * 1993-12-24 2003-08-15 Daiichi Suntory Pharma Co Ltd Benzothiazinderivate
US5874429A (en) * 1993-12-24 1999-02-23 Suntory Limited Benzothiazine derivative
JPH0912562A (ja) * 1995-06-22 1997-01-14 Suntory Ltd 置換ベンゾチアジン誘導体
US6001827A (en) * 1993-12-24 1999-12-14 Suntory Limited Benzothiazine derivative
JP3948744B2 (ja) * 1994-11-04 2007-07-25 大日本住友製薬株式会社 新規なラクタム誘導体
EP0732332B1 (en) * 1995-03-17 2001-12-19 Aventis Pharmaceuticals Inc. Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
US6087364A (en) * 1998-01-29 2000-07-11 Warner-Lambert Company Dopamine D4 receptor antagonists
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US7030142B1 (en) 1999-04-06 2006-04-18 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using ziprasidone metabolites
EP1165083A2 (en) * 1999-04-06 2002-01-02 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
AR028685A1 (es) 2000-06-14 2003-05-21 Lundbeck & Co As H Derivados de indol
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE60327634D1 (de) 2002-08-22 2009-06-25 Dainippon Sumitomo Pharma Co Mittel zur behandlung des integrationsdysfunktionssyndroms
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
EP1637530A4 (en) * 2003-06-23 2009-04-01 Dainippon Sumitomo Pharma Co THERAPEUTIC AGENT FOR SENILE DEMENTIA
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
EP1726952A4 (en) 2004-02-20 2008-06-18 Dainippon Sumitomo Pharma Co METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
GB201102248D0 (en) 2011-02-09 2011-03-23 Isis Innovation Treatment of bipolar disorder
EP2736905A4 (en) * 2011-07-28 2015-07-29 Mapi Pharma Ltd INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF
WO2015014442A1 (en) * 2013-07-31 2015-02-05 Merck Patent Gmbh Oxoquinazolinyl-butanamide derivatives
CN105669665A (zh) * 2016-03-15 2016-06-15 烟台贝森医药科技有限公司 哌罗匹隆的制备方法
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
CN115124464B (zh) * 2022-07-04 2023-06-06 新乡学院 一种喹啉二酮磺酰哌嗪杂合体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2258843B1 (no) * 1974-01-30 1977-09-09 Roussel Uclaf
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
JPH0625181B2 (ja) * 1985-03-27 1994-04-06 住友製薬株式会社 新規なイミド誘導体
JP2660407B2 (ja) * 1986-09-26 1997-10-08 住友製薬株式会社 新規なイミド誘導体
CA1335289C (en) * 1987-10-26 1995-04-18 Fujio Antoku Piperidinyl benzisoxazole derivatives, their production and pharmaceutical use
US5001130A (en) * 1988-02-18 1991-03-19 Bristol-Myers Company Psychotropic heterobicycloalkylpiperazine derivatives
US4780466A (en) * 1988-03-17 1988-10-25 Hoechst-Roussel Pharmaceuticals, Inc. Arylpiperazinylalkoxy derivatives of cyclic imides
NZ230045A (en) * 1988-08-05 1990-11-27 Janssen Pharmaceutica Nv 3-piperazinylbenzazole derivatives and pharmaceutical compositions
US4968792A (en) * 1989-09-25 1990-11-06 American Home Products Corporation Psychotropic benzisothiazole derivatives
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514837A (ja) * 2007-01-03 2010-05-06 コーテックス ファーマシューティカルズ， インコーポレイテッド グルタミン酸作動性シナプス反応を強化するための３−置換−［１，２，３］ベンゾトリアジノン化合物

Also Published As

Publication number Publication date
ZA93958B (en) 1994-08-11
AU3460393A (en) 1993-09-03
EP0625978A1 (en) 1994-11-30
NO942977L (no) 1994-10-10
KR950700290A (ko) 1995-01-16
SK96494A3 (en) 1995-07-11
FI943718A (fi) 1994-08-11
NO942977D0 (no) 1994-08-11
MX9300786A (es) 1994-03-31
CZ194994A3 (en) 1995-09-13
GB9202915D0 (en) 1992-03-25
FI943718A0 (fi) 1994-08-11
WO1993016073A1 (en) 1993-08-19
HU9402343D0 (en) 1994-10-28
CA2117434A1 (en) 1993-08-19
IL104690A0 (en) 1993-06-10
HUT72309A (en) 1996-04-29
RU94038064A (ru) 1997-05-27

Similar Documents

Publication Publication Date Title
JPH07503723A (ja) ピペラジン及びピペリジン誘導体，並びに抗精神薬としてのこれらの使用
ES2200080T3 (es) Derivados de quinolina que tienen propiedades antagonistas de neuroquininas 3.
JP4086663B2 (ja) 新規なスピロ三環式誘導体及びホスホジエステラーゼ７阻害剤としてのそれらの使用
ES2855135T3 (es) Amidas heterocíclicas como inhibidores de quinasa
TW449588B (en) Substituted morpholine derivatives and their use as tachykinin antagonists
ES2219319T3 (es) Derivados de amida.
US20040254373A1 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
JP3421323B2 (ja) ピペリジンｃｃｒ−３受容体拮抗薬
AU2006214184B2 (en) Benzoxazole carboxamides for treating CINV and IBS-D
JP2017522346A (ja) ブロモドメインに対して活性な化合物
JP2005537247A (ja) 置換されたキノリンｃｃｒ５受容体アンタゴニスト
CZ158098A3 (cs) Chinolin-4-karboxamidové deriváty, způsob jejich přípravy, farmaceutický prostředek a použití jako antagonistů receptorů neurokininu 3(NK-3) a 2(NK-2)
CN108290879A (zh) 用作irak抑制剂的杂芳基化合物及其用途
SK160598A3 (en) Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors
ES2201509T3 (es) Derivados de quinolina-4-carboxamida como antagonista de los receptores nk-2 y nk-3.
ES2259096T3 (es) Derivados de quinolina-4-carboxamida 3-sustituida como antagonistas de los receptores nk-3 y nk-2.
WO2014180165A1 (zh) 苯并异噻唑类化合物及在制备抗精神***症药物中的应用
JP2009544657A (ja) 新規なクロメンおよびチオクロメンカルボキサミド誘導体、その製造方法ならびにその治療適用
CA3066328A1 (en) Chemical compounds as atf4 pathway inhibitors
JPH05507281A (ja) ４−（１，２−ベンゾイソキサゾリル）ピペリジン抗精神病薬
JPH07505868A (ja) 置換フェニルカルバメート類および尿素類
KR20190094187A (ko) 축합 고리기 아자시클로부틸 트리아졸 유도체, 이의 제조 방법 및 의약에서의 이의 용도
JPH08506337A (ja) 抗精神活性を有するヘテロ芳香族化合物
ES2204171T3 (es) Derivados de furopiridina y su utilizacion terapeutica.
JPH09509957A (ja) 免疫調節剤としてのキノリン誘導体